NACDS’ VP of pharmacy programs to be honored
EAST HANOVER, N.J. — The Pharmacy Leadership & Education Institute and the Phi Lambda Sigma Pharmacy Leadership Society have selected Alex Adams, VP of pharmacy programs for the National Association of Chain Drug Stores, as the recipient of the 2015 Albert B. Prescott Pharmacy Leadership Award.
The award will be presented on March 29 at the American Pharmacists Association Annual Meeting in San Diego. First presented in 1987, the Prescott Pharmacy Leadership Award is presented to a young pharmacist no more than 10 years into his or her career who has demonstrated exemplary leadership accomplishments.
Adams is responsible for the NACDS’s public health efforts, and also explores innovative services for pharmacy within the transforming healthcare system. He also leads the research efforts of the NACDS Foundation, which has a $5 million portfolio focused on pharmacy-based point-of-care testing, medication adherence interventions, and pharmacy services following hospital discharge, among others.
Previously, Adams worked with Sen. Mark Wagoner, Jr., managing his reelection to the Ohio House of Representatives and his election to the Ohio State Senate.
Senate bill takes aim at curbing drug diversion, abuse
ARLINGTON, Va. — A Senate bill that would help ensure patient access to medications and help curb prescription drug abuse and diversion was introduced last week.
U.S. Sens. Orrin Hatch, R-Utah, and Sheldon Whitehouse, D-R.I., last week introduced S. 483, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015.
The National Association of Chain Drug Stores expressed its support in a letter to Hatch and Whitehouse. In the letter, NACDS stated, “We are pleased to support this legislation, as it would promote comprehensive and consistent strategies to ensure that patients continue to have access to necessary medications, while also addressing and preventing prescription drug diversion and abuse.”
Specifically, S. 483 would direct the Department of Health and Human Services to coordinate with the Drug Enforcement Administration to assess patient obstacles to legitimate access to controlled substances, to identify how collaboration between agencies and stakeholders can benefit patients and prevent diversion and abuse of prescription drugs, and to provide their findings in a report to Congress.
“We are appreciative that this legislation would require HHS and DEA to consult with patient and provider groups, including pharmacies, among other stakeholders,” NACDS stated in its letter. “Pharmacies play an important role in efforts to prevent prescription drug diversion and abuse.”
S. 483 is similar to H.R. 471, which passed out of the House Energy and Commerce Committee last week. Introduced last month in the House by Reps. Tom Marino, R-Pa.; Peter Welch, D-Vt.; Marsha Blackburn, R-Tenn.; and Judy Chu, D-Calif., H.R. 471 also is supported by NACDS.